Published in Appl Environ Microbiol on December 01, 1998
Discovery and in vitro biosynthesis of haloduracin, a two-component lantibiotic. Proc Natl Acad Sci U S A (2006) 2.19
Mapping the pathways to staphylococcal pathogenesis by comparative secretomics. Microbiol Mol Biol Rev (2006) 1.93
Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5. Antimicrob Agents Chemother (2005) 1.79
Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl Environ Microbiol (2009) 1.68
Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin. Appl Environ Microbiol (2006) 1.54
Insights into the mode of action of the two-peptide lantibiotic haloduracin. ACS Chem Biol (2009) 1.32
Bacteriocin (mutacin) production by Streptococcus mutans genome sequence reference strain UA159: elucidation of the antimicrobial repertoire by genetic dissection. Appl Environ Microbiol (2005) 1.31
Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother (2005) 1.30
Dissecting structural and functional diversity of the lantibiotic mersacidin. Chem Biol (2009) 1.25
Production of the novel two-peptide lantibiotic lichenicidin by Bacillus licheniformis DSM 13. PLoS One (2009) 1.14
Production of the Bsa lantibiotic by community-acquired Staphylococcus aureus strains. J Bacteriol (2009) 1.13
Two different lantibiotic-like peptides originate from the ericin gene cluster of Bacillus subtilis A1/3. J Bacteriol (2002) 1.13
Identification of genes encoding two-component lantibiotic production in Staphylococcus aureus C55 and other phage group II S. aureus strains and demonstration of an association with the exfoliative toxin B gene. Infect Immun (1999) 0.95
Identification, characterization, and recombinant expression of epidermicin NI01, a novel unmodified bacteriocin produced by Staphylococcus epidermidis that displays potent activity against Staphylococci. Antimicrob Agents Chemother (2011) 0.93
Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147. Appl Environ Microbiol (2006) 0.87
Manipulation of charged residues within the two-peptide lantibiotic lacticin 3147. Microb Biotechnol (2009) 0.86
Novel LanT associated lantibiotic clusters identified by genome database mining. PLoS One (2014) 0.85
Thusin, a Novel Two-Component Lantibiotic with Potent Antimicrobial Activity against Several Gram-Positive Pathogens. Front Microbiol (2016) 0.85
Relatedness between the two-component lantibiotics lacticin 3147 and staphylococcin C55 based on structure, genetics and biological activity. BMC Microbiol (2007) 0.84
Production and properties of bacteriocin-like inhibitory substances from the swine pathogen Streptococcus suis serotype 2. Appl Environ Microbiol (2003) 0.84
Investigating the importance of charged residues in lantibiotics. Bioeng Bugs (2011) 0.82
Isolation, biochemical characterization, and cloning of a bacteriocin from the poultry-associated Staphylococcus aureus strain CH-91. Appl Microbiol Biotechnol (2012) 0.82
High Frequency and Diversity of Antimicrobial Activities Produced by Nasal Staphylococcus Strains against Bacterial Competitors. PLoS Pathog (2016) 0.76
Mechanistic Understanding of Lanthipeptide Biosynthetic Enzymes. Chem Rev (2017) 0.75
Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective. Front Microbiol (2017) 0.75
The commensal lifestyle of Staphylococcus aureus and its interactions with the nasal microbiota. Nat Rev Microbiol (2017) 0.75
Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem (1987) 59.79
A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem (1977) 36.95
Prepeptide sequence of epidermin, a ribosomally synthesized antibiotic with four sulphide-rings. Nature (1988) 4.41
Genetic analysis of epidermin biosynthetic genes and epidermin-negative mutants of Staphylococcus epidermidis. Eur J Biochem (1992) 3.54
Demonstration of a bactericidal substance against beta-hemolytic streptococci in supernatant fluids of staphylococcal cultures. J Bacteriol (1969) 2.62
A novel lactococcal bacteriocin whose activity depends on the complementary action of two peptides. J Bacteriol (1992) 2.58
Production, purification and chemical properties of an antistaphylococcal agent produced by Staphylococcus epidermidis. J Gen Microbiol (1981) 2.20
Bactericidal substance from Staphylococcus aureus. Biological properties. J Exp Med (1970) 2.11
Epidermin: sequencing of a heterodetic tetracyclic 21-peptide amide antibiotic. Eur J Biochem (1986) 2.04
"Fingerprinting" beta-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. J Med Microbiol (1979) 1.97
Pep5, a new lantibiotic: structural gene isolation and prepeptide sequence. Arch Microbiol (1989) 1.85
Kinetic studies on the interaction of bacteriophage type 71 staphylococcal bacteriocin with susceptible bacteria. J Bacteriol (1973) 1.58
Isolation and characterization of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3. Appl Environ Microbiol (1993) 1.56
Structural gene isolation and prepeptide sequence of gallidermin, a new lanthionine containing antibiotic. FEMS Microbiol Lett (1989) 1.53
Purification and structure of mutacin B-Ny266: a new lantibiotic produced by Streptococcus mutans. FEBS Lett (1997) 1.52
Sequence analysis of lantibiotics: chemical derivatization procedures allow a fast access to complete Edman degradation. Anal Biochem (1994) 1.40
Purification and partial amino acid sequence of plantaricin S, a bacteriocin produced by Lactobacillus plantarum LPCO10, the activity of which depends on the complementary action of two peptides. Appl Environ Microbiol (1995) 1.34
Purification and characterization of plantaricin A, a Lactobacillus plantarum bacteriocin whose activity depends on the action of two peptides. J Gen Microbiol (1993) 1.29
Production and properties of a staphylococcin genetically controlled by the staphylococcal plasmid for exfoliative toxin synthesis. Infect Immun (1977) 1.14
Mitochondrial ATP synthase F1-beta-subunit is a calcium-binding protein. FEBS Lett (1996) 1.06
Factors affecting production of the group A streptococcus bacteriocin SA-FF22. J Med Microbiol (1992) 1.03
Calbindin28kDa and calmodulin are hyperabundant in rat dental enamel cells. Identification of the protein phosphatase calcineurin as a principal calmodulin target and of a secretion-related role for calbindin28kDa. Eur J Biochem (1995) 0.98
Staphylococcin 1580 is identical to the lantibiotic epidermin: implications for the nature of bacteriocins from gram-positive bacteria. Appl Environ Microbiol (1994) 0.96
Purification and characterization of staphylococcin BacR1, a broad-spectrum bacteriocin. Appl Environ Microbiol (1997) 0.93
Lantibiotic-mediated anti-lactobacillus activity of a vaginal Staphylococcus aureus isolate. FEMS Microbiol Lett (1992) 0.91
Sequence analysis by NMR spectroscopy of the peptide lantibiotic epilancin K7 from Staphylococcus epidermidis K7. Eur J Biochem (1995) 0.90
A simple procedure for isolation of cloning vectors and endogenous plasmids from viridans group streptococci and Staphylococcus aureus. Appl Environ Microbiol (1996) 0.89
Enterococcus faecalis cytolysin and lactocin S of Lactobacillus sake. Antonie Van Leeuwenhoek (1996) 0.89
Purification and partial characterization of a novel antibacterial agent (Bac1829) Produced by Staphylococcus aureus KSI1829. Appl Environ Microbiol (1996) 0.86
Isolation of a new epidermin variant from two strains of Staphylococcus epidermidis--frequency of lantibiotic production in coagulase-negative staphylococci. Zentralbl Bakteriol (1996) 0.78
Sequence analysis of dehydroamino acid-containing peptides. Anal Biochem (1994) 0.78
Bacteriocins of gram-positive bacteria. Bacteriol Rev (1976) 10.66
Bacteriocins of gram-positive bacteria. Microbiol Rev (1995) 7.68
Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science (1999) 5.30
Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob Agents Chemother (1985) 3.83
Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem (2000) 3.65
Assay system for bacteriocins. Appl Microbiol (1971) 3.05
Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol Microbiol (1998) 2.69
Production, purification and chemical properties of an antistaphylococcal agent produced by Staphylococcus epidermidis. J Gen Microbiol (1981) 2.20
Mode of action of the staphylococcinlike peptide Pep 5: voltage-dependent depolarization of bacterial and artificial membranes. J Bacteriol (1988) 2.10
Mechanistic studies of lantibiotic-induced permeabilization of phospholipid vesicles. Biochemistry (1995) 2.10
The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. Antimicrob Agents Chemother (1998) 2.06
Dental caries is a preventable infectious disease. Aust Dent J (2000) 1.98
"Fingerprinting" beta-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. J Med Microbiol (1979) 1.97
Interaction of the pore forming-peptide antibiotics Pep 5, nisin and subtilin with non-energized liposomes. FEBS Lett (1989) 1.95
Group A streptococcal bacteriocin. Production, purification, and mode of action. J Exp Med (1973) 1.89
Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis (1999) 1.87
Pep5, a new lantibiotic: structural gene isolation and prepeptide sequence. Arch Microbiol (1989) 1.85
Autolytic system of Staphylococcus simulans 22: influence of cationic peptides on activity of N-acetylmuramoyl-L-alanine amidase. J Bacteriol (1987) 1.82
Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. Arch Microbiol (1985) 1.81
Staphylocidal action of thrombin-induced platelet microbicidal protein is not solely dependent on transmembrane potential. Infect Immun (1996) 1.79
Structural analysis and proteolytic activation of Enterococcus faecalis cytolysin, a novel lantibiotic. Mol Microbiol (1996) 1.71
Influence of the staphylococcinlike peptide Pep 5 on membrane potential of bacterial cells and cytoplasmic membrane vesicles. J Bacteriol (1985) 1.71
Intra- and interspecies signaling between Streptococcus salivarius and Streptococcus pyogenes mediated by SalA and SalA1 lantibiotic peptides. J Bacteriol (2001) 1.63
Bacteriocin of a group B streptococcus: partial purification and characterization. Antimicrob Agents Chemother (1975) 1.59
The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur J Biochem (1997) 1.59
Mode of action of the staphylococcin-like peptide Pep 5 and culture conditions effecting its activity. Zentralbl Bakteriol Mikrobiol Hyg A (1982) 1.58
Isolation and characterization of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3. Appl Environ Microbiol (1993) 1.56
The peptide antibiotic subtilin acts by formation of voltage-dependent multi-state pores in bacterial and artificial membranes. Eur J Biochem (1989) 1.54
Protein engineering of lantibiotics. Antonie Van Leeuwenhoek (1996) 1.54
Bacteriocin of a group A streptococcus: partial purification and properties. Antimicrob Agents Chemother (1973) 1.54
A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol (2006) 1.54
Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism? Antimicrob Agents Chemother (1995) 1.52
Nucleotide sequence of the lantibiotic Pep5 biosynthetic gene cluster and functional analysis of PepP and PepC. Evidence for a role of PepC in thioether formation. Eur J Biochem (1995) 1.50
Structural similarities of the staphylococcin-like peptide Pep-5 to the peptide antibiotic nisin. Antimicrob Agents Chemother (1985) 1.48
Biosynthesis of the lantibiotic Pep5. Isolation and characterization of a prepeptide containing dehydroamino acids. Eur J Biochem (1990) 1.40
Cloning of the gene encoding Streptococcin A-FF22, a novel lantibiotic produced by Streptococcus pyogenes, and determination of its nucleotide sequence. Appl Environ Microbiol (1993) 1.36
Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147. J Biol Chem (1999) 1.29
Isolation, characterization, and heterologous expression of the novel lantibiotic epicidin 280 and analysis of its biosynthetic gene cluster. Appl Environ Microbiol (1998) 1.28
Posttranslationally modified bacteriocins--the lantibiotics. Biopolymers (2000) 1.27
Haemolysin-deficient variants of Streptococcus pyogenes and S. dysgalactiae subsp. equisimilis may be overlooked as aetiological agents of pharyngitis. J Med Microbiol (2000) 1.24
Immunity to lantibiotics. Antonie Van Leeuwenhoek (1996) 1.24
Engineering of a novel thioether bridge and role of modified residues in the lantibiotic Pep5. Appl Environ Microbiol (1996) 1.18
Characterization of Streptococcus zooepidemicus (Lancefield group C) from human and selected animal infections. Epidemiol Infect (1987) 1.16
Construction of an expression system for engineering of the lantibiotic Pep5. Appl Environ Microbiol (1994) 1.16
Cloning, sequencing and production of the lantibiotic mersacidin. FEMS Microbiol Lett (1995) 1.15
Purification and characterization of EpiD, a flavoprotein involved in the biosynthesis of the lantibiotic epidermin. J Bacteriol (1992) 1.14
Elucidation of the structure of SA-FF22, a lanthionine-containing antibacterial peptide produced by Streptococcus pyogenes strain FF22. Eur J Biochem (1994) 1.14
Producer immunity towards the lantibiotic Pep5: identification of the immunity gene pepI and localization and functional analysis of its gene product. Appl Environ Microbiol (1994) 1.14
Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol (2011) 1.13
Novel lantibiotics and their pre-peptides. Antonie Van Leeuwenhoek (1996) 1.12
Epidemiology of Pseudomonas aeruginosa infection in hospitals. 1. Pyocine typing of Ps. aeruginosa. Med J Aust (1971) 1.12
An inhibitor typing scheme for Streptococcus uberis. J Dairy Res (1986) 1.12
Interaction of the staphylococcin-like peptide Pep 5 with cell walls and isolated cell wall components of Gram-positive bacteria. Zentralbl Bakteriol Mikrobiol Hyg A (1985) 1.10
Genotypic and phenotypic analysis of Streptococcus uberis isolated from bovine mammary secretions. Epidemiol Infect (1991) 1.09
A lantibiotic gene family widely distributed in Streptococcus salivarius and Streptococcus pyogenes. Dev Biol Stand (1995) 1.09
Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis (2008) 1.08
Plasmid involvement in production of and immunity to the staphylococcin-like peptide Pep 5. J Gen Microbiol (1984) 1.07
Production of a bacteriocine-like substance by group-A streptococci of M-type 4 and T-pattern 4. J Med Microbiol (1979) 1.06
Lantibiotics--unusually modified bacteriocin-like peptides from gram-positive bacteria. Zentralbl Bakteriol (1993) 1.05
Bacteriocin-like activity of group B and group C streptococci of human and of animal origin. J Hyg (Lond) (1983) 1.04
Different bacteriocin activities of Streptococcus mutans reflect distinct phylogenetic lineages. J Med Microbiol (2002) 1.04
Streptococcus mutans strain N produces a novel low molecular mass non-lantibiotic bacteriocin. FEMS Microbiol Lett (2000) 1.03
Application of inhibitor typing in a study of the transmission and retention in the human mouth of the bacterium Streptococcus salivarius. Arch Oral Biol (1983) 1.03
Factors affecting production of the group A streptococcus bacteriocin SA-FF22. J Med Microbiol (1992) 1.03
Identification and analysis of a gene encoding a Fur-like protein of Staphylococcus epidermidis. FEMS Microbiol Lett (1996) 1.03
New insights into the mechanism of action of lantibiotics--diverse biological effects by binding to the same molecular target. J Antimicrob Chemother (2000) 1.02
Genetic basis of streptococcin A-FF22 production. Antimicrob Agents Chemother (1976) 1.02
Molecular analysis of expression of the lantibiotic pep5 immunity phenotype. Appl Environ Microbiol (1999) 1.02
Elucidation of the primary structure of the lantibiotic epilancin K7 from Staphylococcus epidermidis K7. Cloning and characterisation of the epilancin-K7-encoding gene and NMR analysis of mature epilancin K7. Eur J Biochem (1995) 1.02
The production of bacteriocin-like substances by the oral bacterium Streptococcus salivarius. Arch Oral Biol (1982) 1.00
The biosynthesis of the lantibiotics epidermin, gallidermin, Pep5 and epilancin K7. Antonie Van Leeuwenhoek (1996) 1.00
Some possible autoimmune mechanisms in rheumatic carditis. Lancet (1972) 0.99
Transduction of bacteriocin determinants in group A streptococci. J Exp Med (1976) 0.99
Streptococcin A-FF22: nisin-like antibiotic substance produced by a group A streptococcus. Antimicrob Agents Chemother (1978) 0.97
The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Dis (2005) 0.97
Salivaricin 9, a new lantibiotic produced by Streptococcus salivarius. Microbiology (2011) 0.97
The mode of action of SA-FF22, a lantibiotic isolated from Streptococcus pyogenes strain FF22. Eur J Biochem (1994) 0.96
M-type 57 group A streptococcus bacteriocin. Can J Microbiol (1983) 0.95
Inhibitor production by group-G streptococci of human and of animal origin. J Med Microbiol (1983) 0.95
Identification of genes encoding two-component lantibiotic production in Staphylococcus aureus C55 and other phage group II S. aureus strains and demonstration of an association with the exfoliative toxin B gene. Infect Immun (1999) 0.95
Mode of action of a lysostaphin-like bacteriolytic agent produced by Streptococcus zooepidemicus 4881. Appl Environ Microbiol (1996) 0.92
Beneficial microbes for the oral cavity: time to harness the oral streptococci? Benef Microbes (2011) 0.92
Lantibiotic-mediated anti-lactobacillus activity of a vaginal Staphylococcus aureus isolate. FEMS Microbiol Lett (1992) 0.91
Sequence analysis by NMR spectroscopy of the peptide lantibiotic epilancin K7 from Staphylococcus epidermidis K7. Eur J Biochem (1995) 0.90
Role of bacteriocin during plaque formation by Streptococcus salivarius and Streptococcus sanguis on a tooth in an artificial mouth. J Appl Bacteriol (1981) 0.90
Mechanism of action and limited cross-resistance of new lipopeptide MX-2401. Antimicrob Agents Chemother (2011) 0.90
Production of bacteriocin-like inhibitors by group A streptococci of nephritogenic M types. J Clin Microbiol (1984) 0.89
Molecular characterisation of aureocin A70, a multi-peptide bacteriocin isolated from Staphylococcus aureus. J Mol Biol (2001) 0.89
Use of an inhibitor typing scheme to study the epidemiology of Streptococcus uberis mastitis. N Z Vet J (1988) 0.88
Suspected periodontopathic microorganisms and their oral habitats in young children. Oral Microbiol Immunol (1987) 0.88
Purification and partial characterization of a murein hydrolase, millericin B, produced by Streptococcus milleri NMSCC 061. Appl Environ Microbiol (2000) 0.88
Effects of the lantibiotic mersacidin on the morphology of staphylococci. Zentralbl Bakteriol (1996) 0.87
Production of broad-spectrum bacteriocin-like activity by group A streptococci of particular M-types. Zentralbl Bakteriol Mikrobiol Hyg A (1985) 0.87
Bacteriocin production by group a streptococcal L-forms. Antimicrob Agents Chemother (1976) 0.87
Morphological changes in a susceptible strain of Streptococcus pyogenes treated with streptocin A. J Gen Microbiol (1973) 0.86
Bacteriocin-like inhibitory activity associated with beta-hemolytic strains of Streptococcus salivarius. J Dent Res (1987) 0.86